Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Neoplasm of Uncertain Histogenesis — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Special Category
Neoplasm of Uncertain Histogenesis

Cancer

Neoplasm of Uncertain Histogenesis

CI-CAN-00000034Explore in graph →

Non-malignant20,280 active trials259 approved drugs3,813 evidence items

NCIt: C6974
OncoTree: MBT
UMLS CUI: C1334936

Overview
Statistics
Survival
Genomics465
Variants & evidence3813
Drugs427
Trials91351
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (4,399)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 3,826–3,850 of 4,399 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant.
· Cancer Cell · 2011 · PMID 21575866 · validated civic_curation pubmed
ALK mutations conferring differential resistance to structurally diverse ALK inhibitors.
· Clin Cancer Res · 2011 · PMID 21948233 · validated civic_curation pubmed
Anti-tumor activity of motesanib in a medullary thyroid cancer model.
· J Endocrinol Invest · 2012 · PMID 21422803 · validated civic_curation pubmed
AZD1480 blocks growth and tumorigenesis of RET- activated thyroid cancer cell lines.
· PLoS One · 2012 · PMID 23056499 · validated civic_curation pubmed
Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.
· Cancer Res · 2014 · PMID 24576830 · validated civic_curation pubmed
A genetic progression model of Braf(V600E)-induced intestinal tumorigenesis reveals targets for therapeutic intervention.
· Cancer Cell · 2013 · PMID 23845441 · validated civic_curation pubmed
Vemurafenib synergizes with nutlin-3 to deplete survivin and suppresses melanoma viability and tumor growth.
· Clin Cancer Res · 2013 · PMID 23812671 · validated civic_curation pubmed
Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.

Showing 3,826–3,850 of 4,399 publications

← Previous
1
…
153
154
155
…
176
Next →

· Cancer Res · 2012 · PMID 22180495 · validated civic_curation pubmed

Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma.

· Sci Transl Med · 2011 · PMID 22072639 · validated civic_curation pubmed

FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L).

· Blood · 2005 · PMID 15626738 · validated civic_curation pubmed

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

· J Clin Oncol · 2008 · PMID 18202412 · validated civic_curation pubmed

Identification of targetable FGFR gene fusions in diverse cancers.

· Cancer Discov · 2013 · PMID 23558953 · validated civic_curation pubmed

Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1.

· Blood · 2011 · PMID 21719597 · validated civic_curation pubmed

TSC1 loss synergizes with KRAS activation in lung cancer development in the mouse and confers rapamycin sensitivity.

· Oncogene · 2010 · PMID 19966866 · validated civic_curation pubmed

Promoter methylation of cyclin D2 gene in gastric carcinoma.

· Int J Oncol · 2003 · PMID 14612939 · validated civic_curation pubmed

PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system.

· Clin Cancer Res · 2013 · PMID 23888070 · validated civic_curation pubmed

ESR1 ligand-binding domain mutations in hormone-resistant breast cancer.

· Nat Genet · 2013 · PMID 24185512 · validated civic_curation pubmed

Therapeutic targeting of the cyclin D3:CDK4/6 complex in T cell leukemia.

· Cancer Cell · 2012 · PMID 23079656 · validated civic_curation pubmed

L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition.

· Int J Cancer · 2007 · PMID 17372901 · validated civic_curation pubmed

Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic.

· Proc Natl Acad Sci U S A · 2005 · PMID 15647370 · validated civic_curation pubmed

RNA-seq identifies clinically relevant fusion genes in leukemia including a novel MEF2D/CSF1R fusion responsive to imatinib.

· Leukemia · 2014 · PMID 24186003 · validated civic_curation pubmed

A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer.

· Cancer Cell · 2015 · PMID 25670080 · validated civic_curation pubmed

A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.

· Cancer Res · 2012 · PMID 22440753 · validated civic_curation pubmed

Contribution of ATM and ATR to the resistance of glioblastoma and malignant melanoma cells to the methylating anticancer drug temozolomide.

· Mol Cancer Ther · 2013 · PMID 23960094 · validated civic_curation pubmed

AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol.

· Cancer Cell · 2003 · PMID 12559175 · validated civic_curation pubmed